Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
NanoString Technologies has received FDA 510(k) clearance for its Prosigna breast cancer prognostic gene signature assay. Based on the PAM50 gene signature, Prosigna is the company’s first FDA-cleared in vitro diagnostic assay and uses the gene-expression profile of cells found in breast cancer tissue to assess a patient’s risk of distant recurrence of disease. The Prosigna assay is performed using the nCounter Dx analy
Bleach-Rite Spray, manufactured by Current Technologies, has been approved by the EPA to kill Clostridium difficile spores on hard, nonporous surfaces in five-minute contact time. Bleach-Rite is a hospital-grade spray disinfectant/cleaner, ready to use at the 1:10 dilution recommended by the CDC, OSHA, and NCCLS. The solution is stabilized for an extended shelf life with an expiration date on every bottle.
Illumina launched its TruSight One sequencing panel, which targets 4,813 genes with known associated clinical phenotypes. Clinical research laboratories can use this panel to expand existing menus, streamline workflows, or create an entire portfolio of sequencing options, with benefits including increased productivity, reduced handling errors, and decreased costs.
Hemo Bioscience and Ortho Clinical Diagnostics have developed an exclusive arrangement for distribution of two new HBS products.
Air Science’s Purair Bio safety cabinet is designed to protect individuals, the environment, and products from a variety of biological particulates, serving as the primary barrier in life science research and experimentation.
Enzo Life Sciences’ high-efficiency BioArray conversion kits for detecting 5-mC and 5-hmC modifications (Express DNA methylation kit, blood and tissue DNA methylation kit, and BioArray 5-hmC methylation kit) allow for resolution of single-nucleotide changes without introducing DNA damage. Features such as capacity for multiple sample inputs, rapid processing time, and high-conversion efficiency rate provide enhanced flexibility without sacrificing performance.
The Allegra X-5 air-cooled benchtop centrifuge from Beckman Coulter Life Sciences is designed specifically for clinical sample preparation. Bundled packages, which include swinging bucket rotors and common adapters, enable fast and convenient setup and are offered for a range of clinical sample prep applications.
Clean Collect blood culture kits, available from Stone Medical, prevent contamination of blood cultures using a patented diversion method.
Wheaton CryoELITE tissue vials feature a wide-mouth opening, 5-mL capacity, and high-integrity closure. The vials offer researchers who work with biological tissue sections ease of use, convenience, and security.
PAML, through a partnership with Verinata Health, is now offering the Verifi prenatal test for all patients within the network desiring noninvasive prenatal testing to detect Down syndrome, Edwards syndrome, Patau syndrome, and sex chromosome abnormalities, the most common genetic abnormalities tested for during pregnancy.
